AstraZeneca's T2D Drug BYDUREON BCise Gets Approval In US To Treat Pediatric Patients

AstraZeneca PLC (AZN) on Friday said its BYDUREON BCise has been approved by the Food and Drug Administration to treat type 2 diabetes (T2D) in pediatric patients aged more than 10 years.

The drug is indicated as an adjunct to diet and exercise for improving glycemic control in pediatric patients with T2D.

BYDUREON BCise is the first once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment option for pediatric patients with T2D in the US, the company said.

BYDUREON BCise was approved in the US in 2017 and in the EU in 2018 for the treatment of adults with T2D.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Twitter has rolled out the tipping feature called "Tips" for everyone around the globe using the microblogging site with more payment options to choose from, including cryptocurrencies such as Bitcoin. This is a new way for people to receive and show support on Twitter with money. The feature is currently available on iOS and will be available on Android over the coming weeks. Amazon.com has launched weekly Max-Your-Vax Sweepstakes to encourage their employees to get vaccinated against COVID-19. The sweepstakes began on August 6, 2021 and ends on October 21, 2021, with six draws during the sweepstakes period for 18 prizes worth nearly $2 million, including cash prizes, new vehicle or cash and vacation plus 40 hours of Paid Time Off. Target Corp. announced its plans to hire 100,000 seasonal team members at its stores across the country for this holiday shopping season, though fewer than previous years. With this, the company aims to invest in more flexible scheduling, training, pay and benefits for its existing team members. In a statement, the company said it is also offering around 5 million more hours to its existing staff.
Follow RTT